HELP THE PHILLY PI DELIVER UNBIASED, COMMUNITY-FOCUSED NEWS
The Philly PI relies on reader support to deliver crucial investigative reporting, breaking news, community safety updates, and transparent tech coverage. Independent journalism requires time, deep research, and absolute editorial freedom—free from paywalls, political influence, or corporate control. We cannot keep our newsroom running without you.
100% READER-FUNDED NEWSROOM
NO PAYWALLS OR CORPORATE CONTROL
KEEP INDEPENDENT JOURNALISM FREE FOR ALL
Slightly or heavily decomposed? The more active the soil organisms, the faster…
The remains of Norse buildings on display. The remains of seven Norse…
The next astronauts to walk near the Moon’s south pole will bring…
Their amazing story first started in the dark. Before they became internet…
Could an implant do the job of a workout? In humans, not…
Mpox is back in the headlines, again. Ten confirmed cases in Guinea-Bissau…
Anthropic (ANT) has officially surpassed SpaceX to claim the title of the largest IPO in history, raising $81.34 billion on…

Swiss clinical-stage biotechnology company Windward Bio (WWB) has priced its initial public offering at $17.00 per share, hitting the exact…
Anthropic, the artificial intelligence startup behind the Claude platform, has officially launched terms for its massive $61.05 billion initial public…
Two healthcare enterprises are scheduled to price their initial public offerings during the week of November 9, 2026, aiming to…
Swiss biotechnology firm Windward Bio (WWB Proposed) has set terms for its upcoming $175 million initial public offering on the…
Dental products start-up vVardis Holding AG has officially launched its $214.3 million initial public offering, with pricing expected next week.…
Boston-based clinical-stage biopharmaceutical company Rezera Inc. has set the terms for its upcoming initial public offering, aiming to raise $200…
The U.S. IPO market has started November at a virtual standstill, with no new public offerings scheduled to price this…
Aspen Neuroscience (ASPE), a clinical-stage biotechnology company developing stem cell therapies for Parkinson's disease, priced its initial public offering at…
Sign in to your account